Amivantamab in HPV-unrelated recurrent/metastatic head and neck squamous cell cancer after disease progression on immune checkpoint inhibitor and chemotherapy: Pivotal results from the phase 1b/2 OrigAMI-4 study.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Barbara Burtness, Kevin Joseph Harrington, Dongmei Ji, Benoit Calderon, Sunmin Lim, Muh-Hwa Yang, Shau-Hsuan Li, Shigenori Kadowaki, Paul Swiecicki, Jessica Lyn Geiger, Will Ince, Dennis Hahn, Ye Guo, Douglas Adkins, Joshua C. Curtin, Kiichiro Toyoizumi, Mark S. Wade, Emrullah Yilmaz, Priya Kim, Ari Joseph Rosenberg
Institutions: Yale Cancer Center, Institute of Cancer Research, Royal Marsden Hospital, Shanghai Medical College of Fudan University, Fudan University, Fudan University Shanghai Cancer Center, Institut Sainte Catherine, Severance Hospital, Yonsei University Health System, Yonsei Cancer Hospital, Taipei Veterans General Hospital, Kaohsiung Chang Gung Memorial Hospital, Aichi Cancer Center, University of Michigan, U-M Rogel Cancer Center, Cleveland Clinic, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Klinikum Stuttgart, Tongji University, Shanghai East Hospital, Barnes-Jewish Hospital, Washington University in St. Louis, Alvin J. Siteman Cancer Center, Johnson & Johnson (United States), University of Chicago
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162569758